Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
British Journal of Dermatology2014Vol. 172(2), pp. 484–493
Citations Over TimeTop 1% of 2014 papers
Andrew Blauvelt, Jörg C. Prinz, Alice B. Gottlieb, Külli Kingo, Howard Sofen, M. Ruer‐Mulard, Vijendra K. SINGH, R. Pathan, C. Papavassilis, Simon Cooper, the FEATURE Study Group
Abstract
Secukinumab administration by PFS was effective, with an acceptable safety profile and high usability. The PFS provides a reliable, convenient form of secukinumab administration in subjects with moderate-to-severe plaque psoriasis.
Related Papers
- → A Review of Secukinumab in Psoriasis Treatment(2020)22 cited
- → Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies(2023)16 cited
- → Secukinumab (AIN-457) for the treatment of Psoriasis(2015)13 cited
- → Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs(2021)4 cited
- → AB0639 TREATMENT EFFICACY WITH SECUKINUMAB IN A COHORT OF SPONDYLOARTHRITIS PATIENTS(2020)